Globenewswire·2025-02-28 13:30Core Insights - Nexalin Technology, Inc. has successfully shipped HALO™ Clarity devices for clinical trials aimed at treating mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) in military and civilian populations [1][2] - The clinical trial at the University of California, San Diego (UCSD) follows Institutional Review Board (IRB) approval and will begin patient recruitment immediately [1][2] - The HALO™ Clarity device utilizes proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, which is non-invasive and does not require drugs or invasive procedures [2][3] Company Overview - Nexalin Technology focuses on developing innovative neurostimulation products to address the global mental health crisis, with all products being non-invasive and designed to provide relief for mental health issues [4] - The company employs bioelectronic medical technology to target deep brain structures associated with mental health disorders, aiming for enhanced patient response without adverse side effects [4] - The Nexalin Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, and Oman, indicating the company's international reach and regulatory progress [4] Clinical Trial Details - The initial shipment of HALO devices has been randomized and integrated with an app-controlled remote monitoring system for treatment adherence and progress tracking [3] - An additional 40-50 HALO devices are planned for delivery as the study progresses, highlighting the scalability of the clinical trial [3] - The combination of DIFS technology with a virtual clinic model allows for real-time tracking of patient progress, enhancing the treatment experience [3] Future Outlook - The initiation of patient recruitment is seen as a significant milestone for validating the HALO Clarity device for TBI and PTSD treatment [3] - The company is committed to advancing neurostimulation technologies to meet unmet needs in mental health and neurological care [3]